Citations

Clear

4610 citation(s) found for "Lu, Brian".

Prospective Evaluation of Maintenance Plasma Exchange (mPLEX) for Attack Prevention in Neuromyelitis Optica Spectrum Disorder: Preliminary Feasibility, Safety, and Efficacy Data (P5.265)
Wingerchuk, Dean M. , Weinshenker, Brian, Lennon, Vanda A. , Lucchinetti, Claudia F. , Keegan, Mark , Carter, Jonathan, Pittock, Sean J. , McKeon, Andrew

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p5.265 Get It

Prognostic Factors Affecting ALS Progression through Disease Tollgates (P1-1.Virtual)
Wu, Haoran , He, Qu-Ming, Crum, Brian A. , Erenay, Fatih Safa , Pasupathy, Kalyan S. , Özaltın, Osman Y.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.428 Get It

Incidence of Parkinson Disease in North America (P1-1.Virtual)
Roberts, Eric , Eeden, Stephen Van Den, Savica, Rodolfo , Ross, Web, Marras, Connie , Tanner, Caroline M. , Ross, Webster G., Fiske, Brian , Beck, James C. , Willis, Allison W.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2665 Get It

Clinical Characteristics and Outcomes of Neuroinvasive West Nile virus infection in Immunosuppressed and Immunocompetent individuals treated at the Mayo Clinic Hospitals (P11-9.004)
Gritsch, David , Harahsheh, Ehab , Kasule, Sabirah N, Shemonti, Hasan, Parsons, Angela, Butterfield, Richard , Norville, Kathryn , Reynolds, Jenna , Chong, Brian W. , Grill, Marie , Zhang, Nan , Shiue, Harn

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2114 Get It

Long-term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkuraSky and SAkuraStar Studies (S25.010)
Yamamura, Takashi , Marcillat, Carole, Kou, Xiujing, Weber, Kristina , Blondeau, Kathleen, Patti, F. , Greenberg, Benjamin , Seze, Jerome De , Saiz, Albert , Yeaman, Michael R , Blondeau, Kathleen, Weinshenker, Brian G. , Patti, Francesco

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1354 Get It

Characteristics of childhood intermittent exotropia with and without DVD
Kramer, Andrea M., Klaehn, Lindsay D. , Hodge, David O. , Mohney, Brian G.

Mayo Clinic

Strabismus | December 6, 2023 | Volume: 31 | Issue: 4 | Pages: 290-292

10.1080/09273972.2023.2286379 | PMID 38054427 Get It

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Jain, Michael D. , Jacobs, Miriam T. , Gao, Feng , Nastoupil, Loretta J. , Spiegel, Jay Y. , Dahiya, Saurabh , Lunning, Matthew A. , Lekakis, Lazaros J. , Deol, Abhinav , Sehgal, Alison R. , Hill, Brian T. , Rapoport, Aaron P. , Neelapu, Sattva S. , Dahiya, Saurabh , Oluwole, Olalekan O , McGuirk, Joseph , Deol, Abhinav , Goy, Andre Henri , Andreadis, Charalambos Babis , Munoz, Javier L , Bennani, N Nora , Vose, Julie , Miklos, David B , Neelapu, Sattva S , Ghobadi, Armin , Jain, Michael D , Nastoupil, Loretta J , Jacobs, Miriam T , Lin, Yi , Reagan, Patrick Michael , Oluwole, Olalekan O. , McGuirk, Joseph P. , Muñoz, Javier , Chavez, Julio C , Bennani, N. Nora , Vose, Julie M. , Miklos, David B. , Locke, Frederick L. , Ghobadi, Armin

Mayo Clinic

Blood Advances | December 5, 2023 | Volume: 8 | Issue: 4 | Pages: 1042-1050

10.1182/bloodadvances.2023011489 | PMID 38051550 Get It

Abstract During the manufacturing period of autologous chimeric antigen receptor (CAR) T-cell therapy, patients may experience a decline in their condition due to cancer progression. In this study, we investigated the impact of bridging therapy (BT) on the outcome of patients with relapsed/refractory large B-cell lymphoma who received antilymphoma treatment between leukapheresis and axicabtagene ciloleucel (axi-cel) infusion. We conducted our analysis using data from the multicenter US Lymphoma CAR-T Consortium, with a median follow-up of 33 months (range, 4.3-42.1). Out of the 298 patients who underwent leukapheresis, 275 patients received axi-cel. A total 52% of patients (n = 143) who received BT had a higher baseline risk profile than patients who did not receive BT, and these patients, as a group, had inferior outcomes compared with those who did not receive BT. However, after propensity score matching between the 2 groups, there were no statistically significant differences in overall response rate (77% vs 87%; P = .13), complete response rate (58% vs 70%; P = .1), progression-free survival (hazard ratio [HR], 1.25; P = .23), and overall survival (HR, 1.39; P=.09) between the BT group and the no-BT group, respectively. Analyzing the effects of BT in the whole cohort that underwent leukapheresis regardless of receiving axi-cel (intention-to-treat analysis) showed similar results. Radiation BT resulted in outcomes similar to those observed with nonradiation BT. Our findings suggest that BT may be safe without a significant impact on long-term survival for patients who require disease stabilization during the manufacturing period. Moreover, our results suggest that there is no clear advantage to using radiation-based BT over nonradiation-based BT.
Risk Factors for Surgical-site Infections After Liver Transplant: Does Perioperative Antibiotic Regimen Matter?
Rolak, Stacey , Lahr, Brian D. , Razi, Samrah, Watt, Kymberly D. , Yang, Liu , Aqel, Bashar , Rolak, Stacey C, Watt, Kymberly, Yetmar, Zachary A. , Beam, Elena , Aqel, Bashar A. , Mahmood, Maryam , Yang, Liu

Mayo Clinic

Transplantation | December 4, 2023 | Volume: 108 | Issue: 5 | Pages: 1179-1188

10.1097/tp.0000000000004810 | PMID 38044495 Get It

Background. Surgical-site infections (SSIs) are common in liver transplant recipients. The optimal SSI antimicrobial prophylaxis agent and duration are not established. We aimed to explore risk factors for SSIs after transplant, with a particular interest in the impact of perioperative antibiotic regimen on the development of SSIs. Methods. Retrospective study of adults undergoing liver transplant across 3 transplant programs between January 1, 2020, and June 01, 2021. Results. Of 557 patients included in the study, 32 (5.7%) were infected or colonized with a multidrug-resistant organism (MDRO) within 1 y before liver transplant. Narrow-spectrum SSI prophylaxis with ceftriaxone or cefazolin alone was administered in 488 of 577 patients (87.6%); the remaining 69 patients (12.4%) received broad-spectrum prophylaxis with vancomycin and aztreonam (n = 40), piperacillin–tazobactam (n = 11), carbapenems (n = 8), ceftriaxone and another antibiotic (n = 7), and others. Patients with pretransplant MDRO were more likely to receive broad-spectrum coverage than those without pretransplant MDROs (28.1% versus 11.4%, P = 0.005). SSIs were identified in 40 patients (7.2%); 25 (62.5%) were organ–space infections, 3 (7.5%) were deep incisional infections, and 12 (30.0%) were superficial incisional infections. The median time from liver transplant to SSIs was 14 d (interquartile range, 10–20.2). MDROs were identified in 12 SSIs (30%). Multivariable analysis revealed no significant association between antimicrobial spectrum and risk of SSIs (P = 0.5), whereas surgical leak (P<0.001) and reoperation (P = 0.017) were independently associated with increased risk of SSIs. SSIs were not significantly associated with composite risk of death or liver allograft failure. Conclusions. The spectrum of antimicrobial prophylaxis did not impact the development of SSIs in liver transplant recipients.
An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis
Núñez, Nicolás A. , Kumar, Rakesh , Douka, Ioanna , Miola, Alessandro , Singh, Balwinder , Joseph, Boney , Kumar, Rakesh , Singh, Balwinder , Joseph, Boney , Prokop, Larry J. , Mickey, Brian J.

Mayo Clinic

Brain Sciences | December 2, 2023 | Volume: 13 | Issue: 12 | Pages: 1672

10.3390/brainsci13121672 | PMID 38137120 Get It

Ketamine has shown rapid antidepressant and anti-suicidal effects in treatment-resistant depression (TRD) with single and serial intravenous (IV) infusions, but the effectiveness for depressive episodes of bipolar disorder is less clear. We conducted an updated systematic review and meta-analysis to appraise the current evidence on the efficacy and tolerability of ketamine/esketamine in bipolar depression. A search was conducted to identify randomized controlled trials (RCTs) and non-randomized studies examining single or multiple infusions of ketamine or esketamine treatments. A total of 2657 articles were screened; 11 studies were included in the systematic review of which 7 studies were included in the meta-analysis (five non-randomized, N = 159; two RCTs, N = 33) with a mean age of 42.58 ± 13.1 years and 54.5% females. Pooled analysis from two RCTs showed a significant improvement in depression symptoms measured with MADRS after receiving a single infusion of ketamine (1-day WMD = −11.07; and 2 days WMD = −12.03). Non-randomized studies showed significant response (53%, p < 0.001) and remission rates (38%, p < 0.001) at the study endpoint. The response (54% vs. 55%) and remission (30% vs. 40%) rates for single versus serial ketamine infusion studies were similar. The affective switch rate in the included studies approximated 2.4%. Esketamine data for bipolar depression are limited, based on non-randomized, small sample-sized studies. Further studies with larger sample sizes are required to strengthen the evidence.